Abstract
Background: The benefit of adjuvant chemotherapy is unclear in women aged 70+ with breast cancer. Oncotype DX is a genomic test predicting recurrence risk for women with early oestrogen receptor-positive, HER2-negative, lymph node-negative cancers, for whom chemotherapy side effects may not outweigh the benefits. This study investigated Oncotype DX testing and chemotherapy in women aged 70+, in whom the test is not yet validated.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
